Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GB:0IV3)
LSE:0IV3
Holding GB:0IV3?
Track your performance easily
0IV3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.73 - $5.34
Previous Close$4.49
Volume3.47K
Average Volume (3M)5.52K
Market Cap
$2.72B
Enterprise Value$2.44B
Total Cash (Recent Filing)$362.73M
Total Debt (Recent Filing)$87.04M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 06, 2024EPS Estimate
-$0.09Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding602,795,563
10 Day Avg. Volume4,710
30 Day Avg. Volume5,521
Standard Deviation0.19
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.47
Price to Sales (P/S)2019.56
Price to Cash Flow (P/CF)-13.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.78K
Enterprise Value/Gross Profit10.31K
Enterprise Value/Ebitda-11.79
Forecast
1Y Price Target
$7.50Price Target Upside67.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Geron News
PremiumPre-Earnings
Is GERN a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
FDA Approval And Market AdoptionFollowing the recent FDA approval of Rytelo (imetelstat) in lower-risk myelodysplastic syndrome (LR-MDS).
Market PotentialRytelo's recent adoption within NCCN treatment guidelines boosts confidence in its market potential.
Patent ExtensionA new method patent granted to GERN may extend exclusivity to 2039.
Bears Say
Executive DepartureChief Commercial Officer Anil Kapur will depart.
Leadership ChangeChief Commercial Officer Anil Kapur will be leaving the firm to pursue other interests.
Revenue DependenceRevenue dynamics will depend on patients remaining on therapy.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.74% Insiders
11.84% Mutual Funds
53.14% Other Institutional Investors
33.27% Public Companies and
Individual Investors
0IV3 FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest share price was $1.73 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Currently, no data Available
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 06, 2024 which is in 41 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 08, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.103 by $0.003.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -$0.09.
How many shares outstanding does Geron Corp have?
Geron Corp has 602,795,600 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.103. Following the earnings report the stock price went up 3.943%.
Which hedge fund is a major shareholder of Geron Corp?
Among the largest hedge funds holding Geron Corp’s share is RA Capital Management. It holds Geron Corp’s shares valued at 196M.
---
Geron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (67.22% Upside)
$7.50 (67.22% Upside)
Blogger Sentiment
Bullish
GB:0IV3 Sentiment 90%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.83%
12-Months-Change
Fundamentals
Return on Equity
-72.56%
Trailing 12-Months
Asset Growth
8.21%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
0IV3 Company Deck
---
0IV3 Earnings Call
Q2 2024
0:00 / 0:00
---
0IV3 Stock 12 Month Forecast
Average Price Target
$7.50
▲(67.22% Upside)
Technical Analysis
Geron
―
Adaptimmune Therapeutics
―
Agenus
―
Bioxcel Therapeutics
―
Fate Therapeutics
―
Best Analysts Covering 0IV3
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+49.05%
reiterated a buy rating 2 months ago
Copying Gil Blum's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +49.05% per trade.
---